Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction
about
Role of bile acids in carcinogenesis of pancreatic cancer: An old topic with new perspective.Fatty liver diseases, bile acids, and FXRFarnesoid X Receptor Signaling Shapes the Gut Microbiota and Controls Hepatic Lipid MetabolismGut-Brain Cross-Talk in Metabolic Control.Obesity: Current and potential pharmacotherapeutics and targets.β-Klotho deficiency protects against obesity through a crosstalk between liver, microbiota, and brown adipose tissue.An Intestinal Microbiota-Farnesoid X Receptor Axis Modulates Metabolic Disease.Bariatric surgery and type 2 diabetes: are there weight loss-independent therapeutic effects of upper gastrointestinal bypass?An Intestinal Farnesoid X Receptor-Ceramide Signaling Axis Modulates Hepatic Gluconeogenesis in Mice.Non-alcoholic fatty liver and the gut microbiota.Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives.The antiandrogen flutamide is a novel aryl hydrocarbon receptor ligand that disrupts bile acid homeostasis in mice through induction of Abcc4Recent advances in understanding noroviruses.Conformational modulation of the farnesoid X receptor by prenylflavonoids: Insights from hydrogen deuterium exchange mass spectrometry (HDX-MS), fluorescence titration and molecular docking studies.Strategies for large-scale targeted metabolomics quantification by liquid chromatography-mass spectrometry.Clinical implications of understanding the association between oxidative stress and pediatric NAFLD.Intestinal bile acid receptors are key regulators of glucose homeostasis.Roles of Ileal ASBT and OSTα-OSTβ in Regulating Bile Acid Signaling.Intestinal Farnesoid X Receptor and Takeda G Protein Couple Receptor 5 Signaling in Metabolic Regulation.Microbiota: a key orchestrator of cancer therapy.Bile acids and bariatric surgery.Multi-omic profiles of hepatic metabolism in TPN-fed preterm pigs administered new generation lipid emulsions.Effects of Consuming Xylitol on Gut Microbiota and Lipid Metabolism in Mice.Inhibition of ileal bile acid uptake protects against nonalcoholic fatty liver disease in high-fat diet-fed mice.Host-Microbiota Mutualism in Metabolic Diseases.Modulation of the intestinal bile acid-FXR-FGF15 axis improves alcoholic liver disease in mice.Cyp2c70 is responsible for the species difference in bile acid metabolism between mice and humans.FXR/TGR5 Dual Agonist Prevents Progression of Nephropathy in Diabetes and Obesity.Antibiotic-Induced Alterations in Gut Microbiota Are Associated with Changes in Glucose Metabolism in Healthy Mice.Recent advances in understanding bile acid homeostasis.Effect of Osteocyte-Ablation on Inorganic Phosphate Metabolism: Analysis of Bone-Kidney-Gut Axis.Reciprocal interactions between bile acids and gut microbiota in human liver diseases.Genetic ablation of Cyp8b1 preserves host metabolic function by repressing steatohepatitis and altering gut microbiota composition.Bile acid metabolism in liver pathobiology.Activation of intestinal hypoxia-inducible factor 2α during obesity contributes to hepatic steatosis.Intermittent Fasting Promotes White Adipose Browning and Decreases Obesity by Shaping the Gut Microbiota.Nonalcoholic Fatty Liver Disease as a Nexus of Metabolic and Hepatic Diseases.Omega-3 PUFA ameliorates hyperhomocysteinemia-induced hepatic steatosis in mice by inhibiting hepatic ceramide synthesis.Obeticholic acid improves adipose morphometry and inflammation and reduces steatosis in dietary but not metabolic obesity in mice.Bile acids in glucose metabolism in health and disease.
P2860
Q27693345-DF3871AB-6A63-47C9-88C0-0A472C674C73Q28068199-5468C6E3-22E2-425D-9BA9-409D36AD1602Q28821039-4B00F785-A898-433B-B57B-2FCD95139FFAQ30235568-6DF7C716-D2FB-4609-B3A2-BD9EFDB80777Q30243992-C7FAEAF7-A936-4F11-AE6A-138BB5E31A42Q33578966-266D4EEC-4A71-4505-9FFD-4E0AE3AC49ECQ36136449-5DB0607D-E65E-469E-B7A9-9F9E3CA177C9Q36163431-5E00815A-7A28-4907-8FC3-939DDDF39084Q36287039-BA7D5AF9-6109-46C8-94B7-644FE777DFF7Q37215934-DE3E2078-3FA9-416C-B9AB-02E003829C36Q37538343-CC0511EE-C184-4070-BEBB-4771A5C30E6EQ38749517-D3FB1490-AB8A-47B6-8209-6FFD68BB95ECQ38761262-19598E82-9B31-4998-A600-7155D0724E0AQ38809529-9CAC7E2C-1CEA-4939-96F6-C6CEB6585480Q38976871-04943598-C026-44A5-BB21-9454EF84A23BQ38978486-3DEB19DF-AF4F-41DD-9646-F0F9F611C240Q39009492-94A743A6-6131-4A41-BA4E-E19A3BE05F7BQ39156527-C107987E-5835-47CF-8B46-AD5E57047B93Q39156532-28B00CA6-BBC1-4C27-A2BB-77CB9FAD6483Q39183428-C7EE4B3D-6937-4A83-A6F0-849B1D2EB6FEQ39228891-5694AD2B-B879-417D-9286-03851A632889Q40966013-E8BC2FC2-25DB-4277-B5BD-9E83A6996F7FQ41195441-C90D86B3-451E-4EA5-A26D-2998AA9FAD2AQ41382617-9BC98AD2-6522-4FC9-B71F-A036B394A5E1Q43809679-8AE62F12-A858-4985-BE91-628438467EE2Q45955303-ED81634D-5385-42F1-9858-68107E23EA06Q46488398-2499AFEC-8EEF-42E0-BF0C-E58239CC1221Q46980569-93763014-7558-4D11-AE77-7E10C30DB6A3Q47130145-E439E07F-8D4D-4B85-A838-83C726AB6D29Q47162245-CFA7FE8E-63E9-42DD-A61A-6A684DD2A413Q47221759-3A0623F6-AECD-4766-BC54-380105F0C457Q47389652-DF3CFDE8-F47C-442C-A2A4-0C3929B458D0Q47608553-6C219EBB-902D-4A0F-8F10-D2B70B7592B6Q47645986-AD40AA41-042F-49B8-AEEB-9BBCDF2090ABQ47648812-E5B04E87-EB03-4DEB-AE1E-7099B1261C9AQ47666074-923CCFAC-DB76-483A-AD87-BE4B5C497E9DQ47779219-C377529F-5B76-414F-9831-DD7F82264605Q47877023-2976F599-7E34-4155-93BC-0607EB66D86CQ47958825-C2F4D4E5-A541-42A2-9D3A-D059E8DEA242Q48042610-3214989D-8FB5-40A2-88E2-8A07AF1CCE69
P2860
Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Intestine-selective farnesoid ...... -related metabolic dysfunction
@ast
Intestine-selective farnesoid ...... -related metabolic dysfunction
@en
type
label
Intestine-selective farnesoid ...... -related metabolic dysfunction
@ast
Intestine-selective farnesoid ...... -related metabolic dysfunction
@en
prefLabel
Intestine-selective farnesoid ...... -related metabolic dysfunction
@ast
Intestine-selective farnesoid ...... -related metabolic dysfunction
@en
P2093
P2860
P50
P356
P1476
Intestine-selective farnesoid ...... -related metabolic dysfunction
@en
P2093
Chad N Brocker
Dhimant Desai
Jingmin Shi
Kristopher W Krausz
Oksana Gavrilova
Shantu G Amin
William H Bisson
P2860
P2888
P356
10.1038/NCOMMS10166
P407
P577
2015-12-15T00:00:00Z